SpyGlass Pharma SGP
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$386.8K (7 inflow days, 13 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 70.0% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 3.40% to 3.47% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +366,662 | 2.9% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +226,398 | 2.0% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +59,310 | 0.5% |
| Russell Investment Management, LLC | Mutual Fund | 2026/Q3 | +38,058 | 0.1% |
| TD Asset Management | Mutual Fund | 2026/Q3 | +29,400 | 0.2% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +21,905 | 0.1% |
| Morgan Stanley | Public Company | 2026/Q3 | +21,393 | 0.1% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +21,393 | 0.1% |
| abrdn plc | Mutual Fund | 2026/Q3 | +13,426 | 1.5% |
| ALPS Advisors, Inc. | Mutual Fund | 2026/Q3 | +10,370 | 0.1% |
| JPMorgan Chase & Co. | Public Company | 2026/Q3 | +6,867 | 0.1% |
| Invesco Ltd. | Mutual Fund | 2026/Q3 | +5,568 | 0.0% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +14,649 | 0.0% |
| BlackRock | Mutual Fund | 2026/Q3 | +566,973 | 2.1% |
| abrdn plc | Mutual Fund | 2026/Q3 | +272,622 | 1.5% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 8 Feb 2026 | New Enterprise Associates, Inc. | Private Acquisition | +937,500 | $16.00 | 7,392,301 | |
| 8 Feb 2026 | New Enterprise Associates, Inc. | Derivative Exercise and Retained | +6,454,801 | – | 7,392,301 | |
| 8 Feb 2026 | RA Capital Management, L.P. | Private Acquisition | +3,690,000 | $16.00 | 8,021,117 | |
| 8 Feb 2026 | RA Capital Management, L.P. | Derivative Exercise and Retained | +4,331,117 | – | 8,021,117 | |
| 8 Feb 2026 | Gilde Healthcare Partners BV | Private Acquisition | +312,500 | $16.00 | 2,187,513 | |
| 8 Feb 2026 | Gilde Healthcare Partners BV | Derivative Exercise and Retained | +1,875,013 | – | 2,187,513 | |
| 8 Feb 2026 | Bilal Khan | Independent Director | Private Acquisition | +135,000 | $16.00 | 276,877 |
| 4 Feb 2026 | Scott Sandell | Initial Statement of Beneficial | +0 | – | 737,962 | |
| 4 Feb 2026 | Geoffrey Pardo | Independent Director | Other Derivative Acquisition | +27,400 | $16.00 | 27,400 |
| 4 Feb 2026 | Mohamad Makhzoumi | Initial Statement of Beneficial | +0 | – | 737,962 | |
| 4 Feb 2026 | Elizabeth O'Farrell | Other Derivative Acquisition | +13,700 | $16.00 | 13,700 | |
| 4 Feb 2026 | Elizabeth O'Farrell | Initial Statement of Beneficial | +0 | – | 65,976 | |
| 4 Feb 2026 | RA Capital Management, L.P. | Other Derivative Acquisition | +27,400 | $16.00 | 27,400 | |
| 4 Feb 2026 | RA Capital Management, L.P. | Initial Statement of Beneficial | +0 | – | 494,647 | |
| 4 Feb 2026 | Jean-Frederic Viret | Chief Financial Officer | Other Derivative Acquisition | +17,500 | $16.00 | 17,500 |
| 4 Feb 2026 | Jean-Frederic Viret | Chief Financial Officer | Initial Statement of Beneficial | +0 | – | 263,907 |
| 4 Feb 2026 | Kirk Nielsen | Other Derivative Acquisition | +27,400 | $16.00 | 27,400 | |
| 4 Feb 2026 | Michael Dybbs | Independent Director | Other Derivative Acquisition | +27,400 | $16.00 | 27,400 |
| 4 Feb 2026 | Malik Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | Other Derivative Acquisition | +105,000 | $16.00 | 105,000 |
| 4 Feb 2026 | Malik Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | Initial Statement of Beneficial | +0 | – | 434,738 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 1,160,601 | 3.5% | 12.1 |
| 15 Oct 2026 | 1,224,357 | 3.7% | 15.7 |
| 30 Sep 2026 | 1,253,724 | 3.7% | 7.1 |
| 15 Sep 2026 | 1,229,711 | 3.7% | 11.6 |
| 31 Aug 2026 | 1,096,948 | 3.3% | 15.8 |
| 14 Aug 2026 | 1,136,810 | 3.4% | 15.2 |
No comments yet — be the first to weigh in on SGP.
Sign in to join the discussion.